Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Sep 25, 2012

20 Top-Salaried Research Institute Leaders

Capitalism appears to be alive and well in academia.

20 Top-Salaried Research Institute Leaders

These life science bigwigs are earning the most cash outside of industry. [© Dani Simmonds - Fotolia.com]

  • #10. Leland (Lee) H. Hartwell, Ph.D.

    President and Director, 1997–20105, Fred Hutchinson Cancer Research Center

    $634,183 in FY 2010–2011

  • #9. J. Craig Venter, Ph.D.

    Founder, Chairman, and President, J. Craig Venter Institute

    $645,929 in CY 2010

  • #8. Bruce Stillman, Ph.D.

    President, Cold Spring Harbor Laboratory

    $751,839 in CY 2010

  • #7. Eric S. Lander, Ph.D.

    Founding Director and Director of the Genome Biology Program, Broad Institute

    $818,876 in FY 2010–2011

  • #6. R. Sanders Williams, M.D.

    President, J. David Gladstone Institutes

    $862,505 in CY 2010

  • #5. William R. Brody, M.D., Ph.D.

    President, The Salk Institute for Biological Studies

    $951,743 in FY 2010–2011

  • #4. Jeffrey M. Trent, Ph.D.

    President & Scientific Director, Translational Genomics Research Institute (TGen)

    $1,063,599 in FY 2009–2010

  • #3. Robert Tjian, Ph.D.

    President, Howard Hughes Medical Institute

    $1,143,070 in FY ending Aug. 31, 2011

  • #2. Richard A. Lerner, M.D.

    Director of predecessor organization, 1987–1991; President and CEO, 1991–2012; Researcher, Skaggs Institute for Chemical Biology, 2012-present,The Scripps Research Institute

    $1,370,328 in FY ending Sept. 30, 2010

  • #1. John C. Reed, M.D., Ph.D.

    CEO, Sanford-Burnham Medical Research Institute

    $1,476,406 in FY 2010–2011



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »